Abstract
A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis. This case emphasizes the importance ot considering neoplastic disease as a potential hazard associated with the use of immunosuppressive drugs.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Burnet F. M. Immunological aspects of malignant disease. Lancet. 1967 Jun 3;1(7501):1171–1174. doi: 10.1016/s0140-6736(67)92837-1. [DOI] [PubMed] [Google Scholar]
- Doll R., Kinlen L. Immunosurveillance and cancer: epidemiological evidence. Br Med J. 1970 Nov 14;4(5732):420–422. doi: 10.1136/bmj.4.5732.420. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tolchin S. F., Winkelstein A., Rodnan G. P., Pan S. F., Nankin H. R. Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma). Arthritis Rheum. 1974 Jul-Aug;17(4):375–382. doi: 10.1002/art.1780170406. [DOI] [PubMed] [Google Scholar]